US-guided percutaneous radiofrequency ablation of secondary hyperparathyroidism as a bridge to renal transplantation

• Published in: International journal of hyperthermia 2023-12, Vol.40 (1), p.2223370-2223370
• Main Authors: Yue, Wenwen, Jiang, Tingting, Deng, Erya, Chai, Huihui, Weng, Ning, He, Hongfeng, Zhang, Zhengxian, Xu, Dong, Peng, Chengzhong
• Format: Article
• Language: English
• Subjects: Calcium; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary - surgery; Kidney Transplantation - adverse effects; Parathyroid Hormone; Phosphates; radiofrequency ablation; Radiofrequency Ablation - adverse effects; renal transplantation; Retrospective Studies; thermal ablation
• ISSN: 0265-6736; 1464-5157
• DOI: 10.1080/02656736.2023.2223370

Secondary hyperparathyroidism (SHPT) is a frequently encountered problem in patients with end-stage renal disease (ESRD) prior to renal transplantation (RTP), and the successful management of SPHP currently is challenging. In this study, we aimed to investigate the effectiveness of radiofrequency ablation (RFA) for SHPT as a bridge to RTP and to evaluate post-transplantation outcomes. Patients with SHPT receiving RFA treatment were retrospectively reviewed, and those underwent RTP after ablation were enrolled. Serum parathyroid hormone (PTH), calcium, and phosphate levels were collected before ablation and at follow-up periods. The primary endpoints are PTH values at time of transplantation and at the final follow-up. The secondary endpoints were RFA-related complications, serum calcium and phosphate concentrations, and allograft function. Eleven patients with 43 enlarged parathyroid glands were treated with 16 RFA sessions and enrolled in the study. Complete ablation was achieved in all glands with transient hoarseness and hypocalcemia occurring in two and five of the treatments, respectively. At time of transplantation, serum PTH levels (246.7 ± 182.6 pg/mL) were significantly lower than that before RFA (1666.55 ± 874.48 pg/mL, p